Astrazeneca PLCs in-depth data and chart pattern analysis indicates that the stock price has rallied 13.36% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -8.85% . Looking at the past 52 week period, the stock price is down -0.07% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Astrazeneca PLC has a negative value of -2.98 compared to overall market performance.
AstraZeneca PLC stock has recorded a 20-day Moving Average of 5.59% and the 50-Day Moving Average is 7.92%.The 200 Day SMA reached 2%Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 71.16. Astrazeneca PLC (NYSE:AZN) has climbed 0.65% in the past week and advanced 8.5% in the last 4 weeks. The stocks have underperformed the S&P 500 by 0.04% during the past week but Astrazeneca PLC (NYSE:AZN) it has outperformed the index in 4 weeks by 5.17%.
Astrazeneca PLC (NYSE:AZN) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.16 points or 0.54% at $29.35 with 3,539,599 shares getting traded. Post opening the session at $29.23, the shares hit an intraday low of $29.2 and an intraday high of $29.36 and the price was in this range throughout the day. The company has a market cap of $74,256 million and the number of outstanding shares has been calculated to be 2,530,000,000 shares. The 52-week high of Astrazeneca PLC (NYSE:AZN) is $35.04 and the 52-week low is $25.55.
Institutional Investors own 12.41% of Astrazeneca PLC shares. Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.AstraZeneca plc (ADR) was Upgraded by Leerink Partners to Outperform on Dec 9, 2016.
AstraZeneca plc (ADR) Last issued its quarterly earnings results on Feb 2, 2017. The company reported $1.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $1.18. The company had revenue of $5585.00 million for the quarter, compared to analysts expectations of $5625.25 million. The companys revenue was down -12.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.94 EPS.
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.